本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Redhill Biopharma Ltd

2.35
+0.490026.34%
盘前2.18-0.1700-7.23%06:40 EDT
成交量:2,519.85万
成交额:6,931.48万
市值:539.41万
市盈率:-0.35
高:3.31
开:2.33
低:2.01
收:1.86
数据加载中...
2022/01/27

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/01/11

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2021/08/05

SEC问询函

CORRESP [Cover] - Correspondence
2021/05/27

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2021/05/03

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2021/04/06

SEC问询函

CORRESP [Cover] - Correspondence
2021/03/25

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2021/03/18

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/03/18

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2021/03/02

[补充]招股说明书

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2021/03/01

[补充]招股说明书

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2021/03/01

[补充]招股说明书

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2021/01/15

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/01/12

[补充]招股说明书

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2021/01/11

[补充]招股说明书

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2021/01/11

[补充]招股说明书

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2020/11/12

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/08/13

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/08/13

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/05/27

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]